FindTrial
Sign In

Immunomodulatory Therapy for Severe Novel Coronavirus Pneumonia (COVID-19)

Optimization of treatment and diagnosis plan for critically ill patients

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2000029806
Enrollment
Unknown
Registered
2020-02-14
Start date
2020-02-12
Completion date
Unknown
Last updated
2020-02-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Novel Coronavirus Pneumonia (COVID-19)

Interventions

Thymosin treatment group:Thymosin for injection 1.6 mg sc qd for 5 days
PD-1 treatment group:Camrelizumab 200 mg single dose, diluted to 100 ml intravenous infusion
Conventional treatment group:Conventional treatment

Sponsors

Wuhan Jinyintan Hospital (Wuhan Infectious Diseases Hospital)
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. 2019 adult patients with new-type coronavirus pneumonia diagnosed with 2019-nCoV infection by PCR according to the "Pneumonitis Diagnosis and Treatment Protocol for New-type Coronavirus Infection (Trial Version 5)" 2. The absolute value of lymphocytes =5 cmH2O); 4. Sign the informed consent.

Exclusion criteria

Exclusion criteria: 1. Aged <18 years; 2. Pregnant or lactating women; 3. Allergic to the test drug; 4. The underlying disease is very serious, and the expected survival time is less than 6 months (such as advanced malignant tumors); 5. COPD or end-stage lung disease requires home oxygen therapy; 6. Expected survival time does not exceed 48 hours; 7. Participated in other clinical intervention trials in the past 3 months; 8. Suffering from autoimmune diseases; 9. History of organ, bone marrow or hematopoietic stem cell transplant Received radiotherapy and chemotherapy for malignant tumors within 10.6 months; 11. HIV-infected patients or acquired immune deficiency diagnosed within the past year (CD4 T cells <= 200 / mm3); 12. Patients receiving anti-HCV treatment; 13. 90 days with retinal detachment or eye surgery; 14. Permanent blindness in one eye; 15. History of iritis, endophthalmitis, scleritis, or retinitis; 16. The doctor in charge considers it inappropriate to participate in this study.

Design outcomes

Primary

MeasureTime frame
Proportion of patients with a lung injury score reduction of 1-point or more 7 days after randomization;—

Countries

China

Contacts

Public ContactXia Jiaan

Wuhan Jinyintan Hospital (Wuhan Infectious Diseases Hospital)

3131862959@qq.com+86 13871120171

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026